Prof. Zhijun Yuan 袁志军
Chief Physician, Professor
Department of Medical Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and endocrine therapy for malignancies, especially head and neck tumors, lung cancer, breast cancer, gastrointestinal tumors, and malignant lymphoma.
Dr. Yuan is Chief Physician and Professor at Hunan Cancer Hospital, serving as Deputy Director of the VIP Head and Neck Internal Medicine Ward. With nearly 30 years in clinical oncology chemotherapy, Dr. Yuan is an expert member of the hospital’s Malignant Lymphoma Comprehensive Treatment Group. Research includes multiple provincial projects, two Hunan Medical Science and Technology Awards (third prize), over 20 national publications, and two SCI papers.
Professional roles
- Member, Lymphatic and Hematologic Tumors Committee, Chinese Geriatric Oncology Society
- Vice Chair, Clinical Chemotherapy Professional Committee, Hunan Anti-Cancer Association
- Secretary, Chemotherapy Quality Control Committee, Hunan Province
- Member, Chronic Disease Prevention and Control Professional Committee, Hunan Province
Name order: in Chinese the family name comes first (Yuan Zhijun). Papers usually list the name as Zhijun Yuan or Yuan Z.
Selected publications
9 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMJ Support Palliat Care, 2025 (senior author): High-dose opioids in advanced cancer: use factors-retrospective study. PubMed 39461883
- Am J Transl Res, 2020 (first author): LINC00152 promotes pancreatic cancer cell proliferation, migration and invasion via targeting miR-150. PubMed 32509216
- Onco Targets Ther, 2017 (senior author): MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK/MAPK. PubMed 28331335
- Asian Pac J Cancer Prev, 2015 (first author): Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer. PubMed 26028097
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion